PNEUMOCOCCAL VACCINES
Clinical trials for PNEUMOCOCCAL VACCINES explained in plain language.
Never miss a new study
Get alerted when new PNEUMOCOCCAL VACCINES trials appear
Sign up with your email to follow new studies for PNEUMOCOCCAL VACCINES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pneumonia vaccine VAX-31 aims to boost protection in older adults
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called VAX-31 in adults aged 50 and older who have already received a pneumonia vaccine. The goal is to see if VAX-31 is safe and triggers a strong immune response. About 752 participants will receive either VAX-31 or an active comparator vaccine, a…
Matched conditions: PNEUMOCOCCAL VACCINES
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 02, 2026 00:00 UTC
-
New baby vaccine aims to beat pneumonia: VAX-31 trial underway
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called VAX-31 to protect babies against pneumococcal disease, which can cause pneumonia and meningitis. About 900 healthy infants will receive four doses of VAX-31 or an existing vaccine starting at 2 months old. Researchers will check for side effe…
Matched conditions: PNEUMOCOCCAL VACCINES
Phase: PHASE2 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:32 UTC
-
New combo shot study: could VAX-31 plus flu vaccine be a Game-Changer for seniors?
Prevention OngoingThis study tests a new vaccine called VAX-31, which protects against 31 types of pneumonia-causing bacteria. It is given together with the seasonal flu shot to healthy adults aged 50 and older. The goal is to see if giving both vaccines at the same time is safe and works as well …
Matched conditions: PNEUMOCOCCAL VACCINES
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
New vaccine aims to outsmart pneumonia bacteria
Prevention OngoingThis Phase 3 study is testing a new vaccine called VAX-31 in about 4,000 healthy adults aged 50 and older. The goal is to see if VAX-31 provides better immune protection against more strains of pneumococcal bacteria compared to two current vaccines, Prevnar 20 and Capvaxive. Rese…
Matched conditions: PNEUMOCOCCAL VACCINES
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC